HUTCHMED ( $HCM) Climbs +13% on GSK Deal and Pipeline Momentum (See the latest news for any ticker on Tickeron.) HUTCHMED (HCM) shares climbed roughly 13% over the last 30 days, rising from about $12.38 to near $14.01. The rally was driven primarily by a global licensing agreement with GSK announced on September 3, 2026, covering the antibody-targeted therapy conjugate candidate HMPL-A830. $ACET $CGC $GELS $SNDL $RMTI